Supply of Tolvaptan (Samsca) by Aspen Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted to ensure the quality, efficacy, and safety of therapeutic goods in Australia, was introduced to address the need for a comprehensive regulatory framework governing the supply, advertising, and importation of therapeutic goods. The Act is administered by the Therapeutic Goods Administration, an agency within the Department of Health. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. In a specific instance on October 15, 2013, the delegate of the Secretary of the Department of Health granted consent for Aspen Pharma Pty Ltd to supply tolvaptan products that did not conform to certain labelling requirements under Therapeutic Goods Order No. 69. This consent was provided subject to conditions that ensure the products meet regulatory standards, including the over-sticker of cartons with necessary warnings and information, and the distribution of a 'Dear Pharmacist' letter to advise healthcare practitioners on the proper use of the product.

Scope and Application

The Therapeutic Goods Act 1989, specifically as amended by the notice issued on October 15, 2013, applies to the supply of tolvaptan (SAMSCA) products by Aspen Pharma Pty Ltd. The Act extends to the oversight of therapeutic goods, ensuring that they meet specified standards and requirements before they are supplied in Australia. The notice addresses non-compliance with TGO 69 regarding the Australian sponsor's details on blister labels. This particular legislation affects pharmaceutical entities and their products, ensuring that they adhere to national standards and safety regulations. The jurisdictional reach of the Act is national, applying across all states and territories in Australia. The exclusions or exemptions in this case are limited to the specific conditions outlined in the notice, which include over-sticker requirements and the inclusion of a 'Dear Pharmacist' letter to ensure compliance with the Act’s provisions.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989 (the Act) in this particular notice relate to the supply of therapeutic goods that do not fully comply with the Therapeutic Goods Orders (TGO). Specifically, sections 14 and 14A are invoked here, allowing the delegate of the Secretary of the Department of Health to consent to the supply of tolvaptan (SAMSCA) 15 mg and 30 mg tablet blister packs by Aspen Pharma Pty Ltd, despite the products not conforming to certain regulatory requirements. Section 15(1) of the Act specifies the conditions under which this consent is granted, ensuring that the products are subject to corrective measures before they are supplied to the market. The obligations and requirements imposed on the parties governed by the Act in this instance include the over-stickering of cartons containing the tolvaptan products with essential information such as warning statements, storage conditions, and the Australian sponsor’s details. Additionally, the Act mandates that a 'Dear Pharmacist' letter be included, advising healthcare practitioners to instruct patients to keep the blisters in the cartons. This ensures that the Australian sponsor’s contact details remain visible and accessible, thereby maintaining compliance with regulatory standards. The Therapeutic Goods Act 1989 also delineates the consequences for breach of its provisions. Although the specific offences and penalties are not detailed in this notice, the Act generally provides for both civil and criminal penalties for non-compliance. Civil penalties can include fines, while criminal penalties may involve imprisonment, depending on the severity and intent behind the breach. The maximum penalties can vary significantly based on the specific provisions violated and the nature of the infringement. Therefore, entities such as Aspen Pharma Pty Ltd must ensure strict adherence to the Act to avoid these potential repercussions.